相关实验视频
Updated: Jul 6, 2025

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.8K
-葡萄糖携运输体-2 抑制剂的抗纤维作用:综合性综述
Neda Shakour1, Shima Karami2, Mehrdad Iranshahi3
1Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Diabetes & metabolic syndrome
|December 28, 2023
概括
-葡萄糖携带载体-2 抑制剂 (SGLT2is) 通过保护组织痕,在治疗器官纤维化方面表现有前途. 这些抗糖尿病药物会影响纤维化疾病中关键的细胞过程.
科学领域:
- 药理学 药理学是指药理学的学科.
- 纤维化研究 纤维化研究
- 心血管医学 心血管医学
背景情况:
- 纤维性疾病,以痕组织积累为特征,带来了重大的健康和经济挑战.
- -葡萄糖共传输体-2 抑制剂 (SGLT2is),主要是抗糖尿病药物,表现出超出葡萄糖调节的潜力.
- 器官纤维化会影响许多器官,导致严重的健康并发症.
研究的目的:
- 收集和分析关于SGLT2is.ro的抗纤维作用的现有研究.
- 提出SGLT2is可以对抗纤维化的潜在机制.
- 评估SGLT2is在治疗纤维性疾病中的治疗潜力.
主要方法:
- 在PubMed,ScienceDirect,谷歌学者和Scopus的综合文献搜索.
- 包括2012年至2023年4月间发表的研究.
- 分析详细研究SGLT2is的抗纤维作用的研究.
主要成果:
- SGLT2is对肺部,肝脏,心脏和脏纤维化以及动脉硬产生保护作用.
- 临床试验和动物研究表明,SGLT2is是纤维化治疗的有希望的候选者.
- SGLT2is调节纤维化所涉及的细胞过程,包括缺氧,炎症,氧化应激和代谢活动.
结论:
- 强有力的证据支持SGLT2is作为各种纤维状况的潜在治疗方法.
- SGLT2is在受纤维化影响的多个器官中表现出保护作用.
- SGLT2的抗纤维机制涉及影响关键细胞通路.
相关概念视频
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
177
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
177
Oral Hypoglycemic Agents: Biguanides and Glitazones
206
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
206
Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Secondary Active Transport
120.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
120.1K

